**Perceived sensitivity to medicines: a study among chronic medicine users in Norway**

**Introduction**

Patients’ beliefs and attitudes towards medicines are important drivers of health behaviors. Studies have consistently shown that these factors are strongly associated with patients’ decisions about whether to start and/or continue a needed treatment [1-4]. Patients’ beliefs about medicines may also be highly related to the expectations about the effect of a pharmacological treatment, in terms of effectiveness and/or potential side effects. In 2013 Horne *et al*. developed a five-item scale to measure patients’ perceived sensitivity to medicines (PSM), defined as “the belief that one is especially sensitive to the actions and side effects of medicines” [2]. Despite the importance of understanding factors impacting patients’ medicine taking behavior, little is known about patients’ increased sensitivity to medicines. To date, only one study has explored the prevalence of PSM [5], and found it to be as high as 16% in the general population of New Zealand [5].

Side effects might be related to a known pharmacological or physiological mechanism, they can also be non-specific and driven by the nocebo effect, where negative expectations about a treatment – rather than active ingredients – cause side effects [6]. The nocebo effect is the less well known counterpart of the placebo effect [7]. The placebo-nocebo phenomenon can help to better understand a treatment and how the words affect our brain. As a consequence, the nocebo effect can reduce the potential effectiveness of and adherence to a prescribed treatment [6]. For example, Faasse *et al*, found a relationship between high PSM and increased symptom reporting compared with people who did not view themselves as sensitive to medicines [5]. Similarly, Horne *et al.* found that high PSM predicted elevated symptom reporting after vaccination (r=0.26) [2]. Moreover, other studies have shown that cancer patients who hold negative treatment expectations are more likely to experience unpleasant side effects [8, 9]. It is not yet understood how patients using medicines for chronic disorders perceive their own sensitivity to medicines, and what correlates are associated with high PSM.

**Aim of the study**

This study aimed to i) to explore the extent of and factors associated with high PSM in a Norwegian population of chronic medicine users, ii) and to assess the psychometric characteristics of the PSM in this population. The study focuses solely on increased perceived sensitivity to medicines.

**Ethics approval**

Ethics approval was received by the Norwegian Regional Committees for Medical and Health Research Ethics. The study was reported to the Data Protection Official at the Norwegian Centre for Research Data. Patient gave written informed consent and data were anonymized. Patients could participate in a symbolic (about 100 euro) gift card drawing.

**Methods**

Study design and data collection

This was a cross-sectional study conducted between October 2015 and January 2016 in three community pharmacies located in different areas of Oslo, Norway. Inclusion criteria were age over 18 years, understanding the Norwegian language, and filling a prescription to treat a self-reported chronic disorder (e.g. asthma). All patients filling a prescription were invited to participate in the study. Recruitment took place during different opening hours. Data were collected through a self-administered structured questionnaire. One member of the research team was available at the recruitment sites to answer questions and assist patients in filling out the questionnaires in a separate information room in the pharmacy. The questionnaire was first piloted. Data from the pilot were not included in the analysis. We required a sample size of 246 patients to detect a 20% prevalence of high PSM with a precision of ±5% [5].

## *Measures*

Our outcome variable was patients’ perceived sensitivity to medicines, measured via the validated psychometric instrument PSM [2]. The PSM is a structured, self-reported sensitivity measure with a satisfactory internal consistency (Cronbach’s alpha) of 0.79–0.94 [2, 4, 5]. The PSM scale consists of five items (see Box 1) [2]; patients indicated their degree of agreement with each statement on a 5-point Likert scale (1=strongly disagree to 5=strongly agree). Individual item scores were added, giving a total score of 5-25. A higher score indicates a greater increased sensitivity to medicines. The PSM score was then categorized into three groups: low (5-9), moderate (10-15) and high (16-25) PSM, based on a previous study [5]. Because previous research found no relevant differences between participants with low and moderate PSM scores, these groups were combined in some of the current analyses [5]. The translation from English (original version) to Norwegian, and the back-translation were done by two independent native speakers. Discrepancy between the two English versions was settled by discussion between the two translators. (See Appendix A for the translated version).

Patients’ beliefs about medicines were explored via the 12-item Beliefs About Medicines in General Questionnaire (BMQ-General) [10, 11], which comprises three subscales (4 items each): Harm, Overuse and Benefit. BMQ-General was used to test the psychometric characteristics of the PSM-scale [2]. Patients indicated their degree of agreement with each statement on a 5-point Likert scale (1=strongly disagree to 5=strongly agree). Individual item scores were added, giving a total score of 4-20 for each subscale. Higher scores indicate stronger beliefs in the concepts represented by the subscale. The belief variables were used as continuous in the analysis. A validated Norwegian version of the BMQ-General was used [12].

Patients were asked to self-report which prescription medicine(s) they were dispensed at the pharmacy on the same day of recruitment into the study, by answering the question “Which medicine(s) have you been dispensed today”? Patients could report as free-text entry the name of each medicine, along with information whether this was a treatment for a chronic condition, and whether it was a generic (Yes/No). Based on this information, we estimated how many generics were dispensed at the pharmacy out of all prescriptions filled, and corrected this estimate by the availability of a generic option, using the Norwegian Medicine Agency as reference [13]. The generic variable was then divided into three groups: no generic use (even though there was an available generic option), using < 75% generic medicines, using ≥ 75% generic medicines. Patients having no generic use option were grouped separately. The cut off was pragmatically chosen to provide equal group sizes. Patients were also questioned about any other medicine use via the question “Do you use other medicines (over-the-counter (OTC), e.g. paracetamol, or other prescription medicines)?” If yes, patients could report as free-text entry the name of the other medicines, whether it was OTC or prescription, and frequency of use. All recorded medicines were coded into the corresponding Anatomical Therapeutic Chemical (ATC) codes in accordance with the World Health Organization ATC index [14]. The number of medicines regularly taken was calculated.

Patients were asked about suspected side effects that they had experienced following the use of any medicine. Patients were asked to complete a brief questionnaire consisting of a list of ten commonly reported side effects (e.g., muscle pain, nausea, dizziness), selected according to prior literature [15]. For each side effect, patients were asked whether they had every experienced it (Yes/No), and were also able to make comments via free-text entry. The number of suspected side effects was then summed.

Patients reported the number of visits they had made to their GP in the previous year (0, 1-2, 3-5, >5, cannot remember), whether they were currently using vitamins and/or supplements (Yes/No/Cannot remember) and if yes, which ones. The total number of all reported vitamins and supplements was also assessed and summed. Information about patient information leaflet (PIL) reading before starting a new medicine was collected.

Patients sociodemographics included gender, age, native language, marital status, annual household income, level of education, and health-related education or a family member with health education (categorized as in Table 1). We assessed the study’s external validity by comparing the distribution of age and gender in the sample with that of the Norwegian general population filling specific prescriptions in 2015 in Oslo (via the Norwegian Prescription Database) (Appendix B).

*Statistical analyses*

The Pearson chi-square and the Student's t-test were used to compare proportions and mean scores between independent groups, respectively. The psychometric characteristics of the PSM were assessed by measuring the extent of completion (%, acceptability), the internal consistency (Cronbach’s alpha), and the PSM correlation with a) three BMQ-general subscales, and b) number of reported side effects c) total number of generics [2]. The Pearson and Spearman correlation coefficients were used to relate the BMQ-general subscales with number of reported side effects and generics. This was done to test if PSM is a related, but a separate domain from BMQ. A p-value of <0.05 was considered statistically significant. To test the robustness of the correlation with PSM and number of reported side effects, item 4 was excluded.

Univariate and multivariate generalized estimation equations (GEE) with a binomial distribution (high versus moderate/low PSM) was fit to account for clustering within the reported chronic disorders [16]. The multivariate model was built after fitting the univariate model for all explanatory variables. Purposeful selection of candidate variables was done based on a univariate p-value<0.20. We fitted a reduced model by removing variables having no role (p-value>0.05) or yielding a change smaller than 15% in the beta coefficients of the retained variables [17]. A listwise deletion approach was applied. Data are presented as crude (OR) and adjusted odds ratios (aOR) with 95% confidence intervals (CI). As a sensitivity analysis a regular multivariate logistic model was carried out. All statistical analyses were performed using SPSS 22.0 (SPSS Inc., Chicago, IL, USA).

**Results**

The study included 218 chronic medicines users (response rate 36.7%) of which four were excluded, because of missing values on the PSM. This resulted in a final sample of 214 patients. The sample characteristics and the reported chronic disorders by PSM level are presented in Table 1 and Appendix C, respectively. Overall, 60.7% of participants were women and mean age was 62.3 years (SD: 15.2; range: 23-93 years). On average the patients used 5.7 regular medicines (SD: 2.7; range: 2-16), and 1.5 supplements (SD: 1.4; range: 1-7).

Table 2 outlines the degree of agreement with each individual PSM item. In the sample, the total PSM mean score was 12.2 (SD: 3.9; median 12) (Appendix D). On the basis of the PSM, 20.1% of the patients presented low perceived sensitivity to medicines, 61.7% moderate and 18.2% high (Appendix E). Patients with high PSM more often reported experiencing side effects such as dizziness, headache, constipation compared to patients with low/moderate PSM (Fig. 1).

The crude and adjusted results are presented in Table 3. Four factors were found to be independently associated with high PSM. Specifically, women or patients with a native language other than Norwegian had about 5-fold increased odds of having high PSM compared with men or native Norwegians. Acceptance of some generic substitution was associated with lower perceived sensitivity to medicines, and patients with high school education were less likely to view themselves as highly sensitive to medicines when compared to those with tertiary education. Similar association measures and overlapping confidence intervals were found in regular logistic analysis (results not shown).

The PSM was acceptable (98.2% completion), and with good internal consistency (Cronbach’s alpha: 0.83. The PSM correlated negatively with the BMQ-benefit (r=-0.22; p=0.001), and total numbers of generics (r=-0.14; p=0.038). The PSM correlated positively with the BMQ-harm (r=0.27; p<0.001), BMQ-overuse (r=0.22; p=0.002), reported side effects (r=0.46; p<0.001; item 4 excluded: r=0.39; p<0.001). There was no significant correlation between any of the BMQ subscales and number of reported side effects. BMQ-overuse correlated negatively with numbers of generics (r=-0.18; p<0.009).

**Discussion**

In this study, almost one out of five patients had high self-reported PSM, and one out of two reported experiencing side effects to medicines in the past. High perceived sensitivity appears to be a common belief among Norwegian medicine users, and our estimate (18.2%) was similar to that observed in the general population in New Zealand (15.8%) [5]. The number of experienced side effects could explain about 20% of the PSM variance. These findings may suggest that patients with high self-reported PSM hold negative expectations about treatments, which could in turn trigger a nocebo effect. Likewise, it is also possible that negative past experiences with medicines may shape perceptions of medicine sensitivity. Regardless of the direction of this relationship, both negative expectations and the experience of unpleasant side effects can make patients reluctant to start or continue an otherwise beneficial and necessary treatment, as well as contributing to poor adherence [1, 2, 5, 18]. There is growing evidence that expecting side effects, makes them significantly more likely to occur [8, 19]. Indeed, patients have been found to report similar rates of many side effects independent of being in the treatment or placebo control group, even in randomized controlled trials [5, 20, 21].

Three findings from the current study point to PSM being part of a more general network of negative beliefs about medicines, and not just a specific response to an unpleasant medicine experience. First, PSM scores were negatively correlated with beliefs about the broad benefits of medicines, and positively correlated with perceptions of medicines as being harmful and overused. Second, there was no association between perceived sensitivity and the number of prescription medicines that patients reported taking. Third, while 54.2% of respondents reported having a bad reaction to medicines in the past, only 20.6% endorsed the idea that their body was very sensitive to medicines. These findings indicate that experience of poor reactions to medicines, alone, are not sufficient to generate the perception of heightened sensitivity. We propose that the perception of high personal sensitivity to medicines may contribute to a vicious cycle, in which negative expectations (high PSM) contribute to the experience of more treatment side effects via the nocebo effect, which further reinforces perceived sensitivity. This is often referred to as the concept of pharmaceutical schema: a pattern of beliefs about pharmaceuticals [10, 22, 23].

A key finding is that patients who accepted generic substitution were less likely to be categorized as having high PSM compared to users of branded drugs alone (59-88% odds reduction). This association supports a link between a belief (PSM), and an objectively assessed behavioral outcome (use of generic medicines). Patients often state that generics are not an equal alternative to branded drugs [24]. Brand name medicines may offer a sense of reassurance and a promise of efficacy and safety to already concerned patients [25]. Patients’ trust in and willingness to use generic medicines varies, and depends on both sociodemographic factors as well as attitudes, beliefs, and experiences [26]. Thus, the PSM presents a useful indicator of general side effect expectations, which is conceptually related to both nocebo effects and generic medicine use [2, 26].

Gender, immigrant status, and educational level, were the sole patients’ characteristics independently associated with high PSM. This battery of correlates can however aid health care providers in the identification of patients at risk of high sensitivity to medicines. Women viewed themselves as more sensitive to medicines compared to men, as identified in earlier studies [5, 18]. The established gender differences in pharmacokinetics and pharmacodynamics, health behavior and physical symptom reporting, may not entirely explain the association between PSM and gender [27-29]. It is possible that females are more inclined to information seeking [30-32], including information about possible treatment side effects [33]. Patients with high school education were less likely to report sensitivity to medicines. Less educated people appear to be less likely to seek health information [34] or ask questions during medical encounters [35]. It might be that that less information about side effects may have a ‘protective’ effect on some patients. The results of the current study parallel the finding that parents with lower levels of education held more positive views of vaccination [36].

One strength of this study is the focus on patients taking medicines for chronic disorders, an important group of the population in relation to perceived sensitivity to medicines and the reporting of adjusted measures of association with PSM. The PSM scale has been previously validated although this study was the first utilizing the Norwegian version of the PSM [2]. Yet, this PSM version demonstrated good psychometric characteristics, and a criterion-related validity in the range and similar direction as previously described [2, 4, 5]. The PSM cut-off scores are not validated, instead based on a previous study [5]. Further, all items on the PSM scale are negatively worded, which can influence participant responding. One notable limitation is the low response rate (36.7%). The main reason given for declining was lack of time to complete the questionnaire, which was estimated to take about 15-20 minutes. The proportion of patients within some subgroups, such as non-Norwegian native language, was low. Another limitation is the cross-sectional nature of the study: we cannot establish whether high perceived sensitivity resulted in more side effects, or the converse. Patients filling a prescription were randomly asked to participate in the study, however we cannot rule out the possibility of selection bias. The study did not measure medication adherence and its association to PSM, as done in prior research [2]. The research team member could solely provide technical supports to patients, i.e. where to fill out; thus, the risk of bias due to the team member influence on patients’ responses is likely to be minimal. In Norway patients are aware that they are being dispensed a generic medicine, which may not be the case in other countries. Thus, our observed negative association between taking generics and high PSM may not be of relevance in countries where patients are unaware of the dispensed medicine type (i.e., whether it is a generic medicine, a branded generic, or a branded medicine). Recruitment took place only in the capital of Norway; thus extrapolation of our finding to the general Norwegian population of medicine users should be done keeping these limitations in mind. Nevertheless, the characteristics of the sample were similar to those of the general prescription fillers in Oslo as regards age and gender. The precision of detecting high PSM in our sample is +/-6.0%. Still, our findings must be interpreted with these limitations in mind.

**Conclusion**

In this Norwegian population of patients using medicines for chronic disorders, almost one out of five patients had a high self-reported perceived sensitivity to medicines, and the Norwegian PSM version presented good validity. The factors positively associated with high PSM were female gender and having a non-native language; lower educational level and using generic medicines were negatively associated with high PSM. These findings points to the need for greater awareness about patient perceptions of their personal sensitivity to medicines among health care providers.

***Conflicts of interest***

No conflict of interest.

***Acknowledgements***

The authors would like to express our gratitude to all patients participating in the study and to the three pharmacies for their invaluable help in data collection.

***Funders***

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

**References**

1. Nestoriuc Y, Orav EJ, Liang MH, Horne R, Barsky AJ. Prediction of nonspecific side effects in rheumatoid arthritis patients by beliefs about medicines. Arthritis Care Res (Hoboken). 2010;62(6):791-9.

2. Horne R, Faasse K, Cooper V, Diefenbach MA, Leventhal H, Leventhal E, et al. The perceived sensitivity to medicines (PSM) scale: an evaluation of validity and reliability. Br J Health Psychol. 2013;18(1):18-30.

3. Espay AJ, Norris MM, Eliassen JC, Dwivedi A, Smith MS, Banks C, et al. Placebo effect of medication cost in Parkinson disease: a randomized double-blind study. Neurology. 2015;84(8):794-802.

4. Andersson Sundell K, Jonsson AK. Beliefs about medicines are strongly associated with medicine-use patterns among the general population. Int J Clin Pract. 2016;70(3):277-85.

5. Faasse K, Grey A, Horne R, Petrie KJ. High perceived sensitivity to medicines is associated with higher medical care utilisation, increased symptom reporting and greater information-seeking about medication. Pharmacoepidemiol Drug Saf. 2015.

6. Faasse K, Petrie KJ. The nocebo effect: patient expectations and medication side effects. Postgrad Med J. 2013;89(1055):540-6.

7. Stewart-Williams S, Podd J. The placebo effect: dissolving the expectancy versus conditioning debate. Psychol Bull. 2004;130(2):324-40.

8. Colagiuri B, Zachariae R. Patient expectancy and post-chemotherapy nausea: a meta-analysis. Ann Behav Med. 2010;40(1):3-14.

9. Nestoriuc Y, von Blanckenburg P, Schuricht F, Barsky AJ, Hadji P, Albert US, et al. Is it best to expect the worst? Influence of patients' side-effect expectations on endocrine treatment outcome in a 2-year prospective clinical cohort study. Ann Oncol. 2016;27(10):1909-15.

10. Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health. 1999;14(1):1-24.

11. Wei L, Champman S, Li X, Li X, Li S, Chen R, et al. Beliefs about medicines and non-adherence in patients with stroke, diabetes mellitus and rheumatoid arthritis: a cross-sectional study in China. BMJ Open. 2017;7(10):e017293.

12. Jonsdottir H, Friis S, Horne R, Pettersen KI, Reikvam A, Andreassen OA. Beliefs about medications: measurement and relationship to adherence in patients with severe mental disorders. Acta Psychiatr Scand. 2009;119(1):78-84.

13. The Norwegian Medicines Agency (NoMA). NoMA medicine database («legemiddelsøk»). 2016. https://www.legemiddelsok.no/sider/Default.aspx?pane=2&f=Han%3bVir%3bRef%3bMar%3bAvr%3bpar%3bgen. Accessed 30 March 2016.

14. WHO Collaborating Centre for Drugs Statistics Methodology. ATC/DDD index 2012. http://www.whocc.no/atc\_ddd\_index/. Accessed 17 March 2016.

15. Tan K, Petrie KJ, Faasse K, Bolland MJ, Grey A. Unhelpful information about adverse drug reactions. BMJ. 2014;349:g5019.

16. Kirkwood BR, Sterne JAC. Essential medical statistics. 2nd ed. ed. Malden: Blackwell; 2003.

17. Hosmer DW, Lemeshow S, Sturdivant RX. Applied Logistic Regression. 3rd ed. ed. Hoboken: Wiley; 2013.

18. Chapman SCE, Horne R, Chater A, Hukins D, Smithson WH. Patients' perspectives on antiepileptic medication: Relationships between beliefs about medicines and adherence among patients with epilepsy in UK primary care. Epilepsy Behav. 2014;31:312-20.

19. Laferton JA, Kube T, Salzmann S, Auer CJ, Shedden-Mora MC. Patients' Expectations Regarding Medical Treatment: A Critical Review of Concepts and Their Assessment. Front Psychol. 2017;8:233.

20. Gupta A, Thompson D, Whitehouse A, Collier T, Dahlof B, Poulter N, et al. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial&#x2014;Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. The Lancet.

21. Preston RA, Materson BJ, Reda DJ, Williams DW. Placebo-associated blood pressure response and adverse effects in the treatment of hypertension: observations from a Department of Veterans Affairs Cooperative Study. Arch Intern Med. 2000;160(10):1449-54.

22. Heller MK, Chapman SCE, Horne R. No blank slates: Pre-existing schemas about pharmaceuticals predict memory for side effects. Psychol Health. 2017;32(4):402-21.

23. Horne R. Treatment perceptions and self-regulation. In: Leventhal H, Cameron LD, editors. The Self-regulation of health and illness behaviour. London: Routledge; 2003.

24. Kjoenniksen I, Lindbaek M, Granas AG. Patients' attitudes towards and experiences of generic drug substitution in Norway. Pharm World Sci. 2006;28(5):284-9.

25. Chandler J, & Owen, M. Pharmaceuticals: the new brand arena. International Journal of Market Research. 2002;44(4):385–404.

26. Dunne SS, Dunne CP. What do people really think of generic medicines? A systematic review and critical appraisal of literature on stakeholder perceptions of generic drugs. BMC Med. 2015;13:173.

27. Gandhi M, Aweeka F, Greenblatt RM, Blaschke TF. Sex differences in pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol Toxicol. 2004;44:499-523.

28. Schwartz JB. The current state of knowledge on age, sex, and their interactions on clinical pharmacology. Clin Pharmacol Ther. 2007;82(1):87-96.

29. Petrie KJ, Faasse K, Crichton F, Grey A. How common are symptoms? Evidence from a New Zealand national telephone survey. BMJ Open. 2014;4(6):e005374.

30. Nolke L, Mensing M, Kramer A, Hornberg C. Sociodemographic and health-(care-)related characteristics of online health information seekers: a cross-sectional German study. BMC Public Health. 2015;15:31.

31. Manierre MJ. Gaps in knowledge: tracking and explaining gender differences in health information seeking. Soc Sci Med. 2015;128:151-8.

32. Hallyburton A, Evarts LA. Gender and Online Health Information Seeking: A Five Survey Meta-Analysis. Journal of Consumer Health on the Internet. 2014;18(2):128-42.

33. Swedish Medical Product Agency. Årsrapporter, biverkningsarbetet. Årsrapprt for biverkningar 2016. https://lakemedelsverket.se/biverkningsrapporter. Accessed 21 October 2017.

34. Richardson A, Allen JA, Xiao H, Vallone D. Effects of race/ethnicity and socioeconomic status on health information-seeking, confidence, and trust. J Health Care Poor Underserved. 2012;23(4):1477-93.

35. Street LR, Gordon SH, Ward MM, Krupat LE, Kravitz LR. Patient Participation in Medical Consultations: Why Some Patients are More Involved Than Others. Med Care. 2005;43(10):960-9.

36. Brewer NT, Fazekas KI. Predictors of HPV vaccine acceptability: a theory-informed, systematic review. Prev Med. 2007;45(2-3):107-14.

|  |
| --- |
| **Table 1.** Frequency of background characteristics of the study population, according to level of perceived sensitivity to medicines (PSM). |
|  | **Low/moderate****PSM (n=175)** | **High PSM (n=39)** | **Total (n=214)** |
| **Gender n (%)** |  |  |  |
| Female\*\*\* | 97 (55.4) | 33 (84.6) | 130 (60.7) |
| **Age (years) mean ± SD** | 63.1; 15.3 | 58.7; 14.3 | 62.3; 15.2 |
| **Native language n (%)** |  |  |  |
| Norwegian | 147 (84.0) | 29 (74.4) | 176 (82.2) |
| Other | 26 (14.9) | 10 (25.6) | 36 (16.8) |
| **Marital status n (%)** |  |  |  |
| Married or cohabiting | 100 (57.1) | 22 (56.4) | 122 (57.0) |
| Other† | 75 (42.9) | 17 (43.6) | 92 (43.0) |
| **Annual income for the household (€)**‡**\* n (%)** |  |  |  |
| Low | 47 (29.9) | 11 (28.2) | 58 (27.1) |
| Medium | 59 (33.7) | 16 (41.0) | 75 (35.0) |
| High | 51 (29.1) | 8 (20.5) | 59 (27.6) |
| **Educational level**§**\* n (%)** |  |  |  |
| High school | 81 (46.3) | 16 (41.0) | 97 (45.3) |
| University/College | 63 (36.0) | 21 (53.8) | 84 (39.3) |
| Other education | 30 (17.1) | 2 (5.1) | 32 (15.0) |
| **Health-related education\* n (%)** |  |  |  |
| Yes | 39 (22.3) | 14 (35.9) | 53 (24.8) |
| No | 132 (75.4) | 22 (56.4) | 154 (72.0) |
| I do not know | 4 (2.3) | 3 (7.7) | 7 (3.3) |
| **Family member with health-related education n (%)** |  |  |  |
| Yes | 62 (35.4) | 21 (53.8) | 83 (38.8) |
| No | 111 (63.4) | 18 (46.2) | 129 (60.3) |
| I do not know | 2 (1.1) |  | 2 (0.1) |
| **Number of regular medicines taken m ± SD** | 5.9; 2.7 | 5.3; 2.8 | 5.7; 2.7 |
| **Use of OTC n (%)** |  |  |  |
| No | 99 (56.6) | 24 (61.5) | 123 (57.5) |
| Yes | 76 (43.4) | 15 (38.5) | 91 (42.5) |
| **Number of supplements taken m ± SD** | 1.4; 1.4 | 1.7; 1.6 | 1.5; 1.4 |
| **Generic substitution**¶**n (%)** |  |  |  |
| No | 52 (29.7) | 17 (43.6) | 69 (32.2) |
| < 75% | 49 (28.0) | 5 (12.8) | 54 (25.2) |
| ≥ 75% | 49 (28.0) | 11 (28.2) | 60 (28.0) |
| **Patient information leaflet** **reading n (%)\*\*** |  |  |  |
| Never/sometimes | 86 (49.1) | 10 (25.6) | 96 (44.9) |
| Always | 89 (50.9) | 29 (74.4) | 118 (55.1) |
| **GP visits in a year n (%)** |  |  |  |
| 0-2 | 49 (28.0) | 10 (25.6) | 59 (27.6) |
| 3-5 | 68 (38.9) | 15 (38.5) | 83 (38.8) |
| >5 | 51 (29.1) | 12 (30.8) | 63 (29.4) |
| Cannot remember | 7 (4.0) | 2 (5.1) | 9 (4.2) |
| Numbers do not add up due to missing numbers. Missing values were < 4 % for all variables, except annual income (n=22; 10.3%). \*< 0.05; \*\*≤ 0.01 \*\*\*≤ 0.001†: Single, divorced or other.‡: If one was married or registered partnership and had total income: <43 057 or 43 057 -64 478€, was categorized as low income; 64 586-86 006 € you were categorized as medium income; >86 114€ you were categorized as high income. If you were divorced/ widow/widower/not married or other and had total income: < 43 057€ you were categorized as medium income; > 43 057€ you were categorized as high income. 1 Euro= 9.29 NOK, annual exchange rate for 2016.[10]§: High school education indicates secondary education with 9-12 years of education, and also education other than tertiary.¶: The generic variable was then divided into three groups: no generic use (even though there was an available generic brand), using < 75% generic medicines, using ≥ 75% generic medicines. Patients with no choice of a generic substitution n=34 (14.2%). |

|  |
| --- |
| **Table 2.** Mean(± (±SD) and median for the Perceived Sensitivity to Medicines (PSM) scale of individual items and numbers and percentages of individuals who agreed disagreed with the items (n=214). |
| Item | Mean (SD) | Strongly disagree | Disagree | Neither agreeor disagree  | Agree | Strongly agree |
|  |  | n (%) | n (%) | n (%) | n (%) | n (%) |
| My body is very sensitive to medicines | 2.5 (1.1) | 25 (11.7) | 107 (50.0) | 38 (17.8) | 31 (14.5)  | 13 (6.1)  |
| My body overacts to medicines | 2.2 (0.9) | 34 (15.9) | 129 (60.3) | 32 (15.0) | 15 (7.0)  | 4 (1.9)  |
| I usually have a stronger reaction to medicines than most people I know | 2.0 (0.9) | 55 (25.7) | 115 (53.7) | 30 (14.0)  | 9 (4.2) | 5 (2.3) |
| I have had a bad reaction to medicines in the past | 3.2 (1.2) | 21 (9.8) | 51 (23.8) | 26 (12.1)  | 101 (47.2) | 15 (7.0) |
| Even small amounts of medicine can upset my body | 2.2 (1.0) | 46 (21.5) | 108 (50.5) | 34 (15.9)  | 20 (9.3) | 6 (2.8) |
| © Professor Rob Horne University of London, 2013 |

|  |
| --- |
| **Table 3**: Prediction model of factors associated with high Perceived Sensitivity to Medicines PSM (n=214). |
|  | **Model 1**† |  | **Model 2**‡ |
|   | **OR** | **95% CI**  |  | **OR** | **95% CI** |
| **Gender** |  |  |  |  |  |
| Male | 1 |  |  | 1 |  |
| Female | **4.42** | **1.76-11.09** |  | **5.33** | **1.52-18.72** |
| **Age (years)**§ | 0.98 | 0.96-1.00 |  |  |  |
| **Native language** |  |  |  |  |  |
| Norwegian | 1 |  |  | 1 |  |
| Others | 1.95 | 0.85-4.48 |  | **4.76** | **1.48-15.30** |
| **Marital status** |  |  |  |  |  |
| Married/registered partnership | 1 |  |  |  |  |
| Other | 1.03 | 0.51-2.08 |  |  |  |
| **Household income**¶ |  |  |  |  |  |
| Medium  | 1 |  |  |  |  |
| Low | 0.86 | 0.37-2.04 |  |  |  |
| High | 0.58 | 0.23-1.46 |  |  |  |
| **Educational level**Ϊ |  |  |  |  |  |
| University/College  | 1 |  |  | 1 |  |
| High school | **0.49** | **0.24-0.98** |  | **0.43** | **0.17-1.07** |
| **Health-related education** |  |  |  |  |  |
| No | 1 |  |  |  |  |
| Yes | **2.15** | **1.01-4.60** |  |  |  |
| **Family member with health-related education** |  |  |  |  |  |
| No | 1 |  |  |  |  |
| Yes | **2.09** | **1.04-4.22** |  |  |  |
| **Number of regular medicines taken** | 0.92 | 0.80-1.07 |  |  |  |
| **Use of OTC** |  |  |  |  |  |
| No | 1 |  |  |  |  |
| Yes | 0.81 | 0.40-1.66 |  |  |  |
| **Number of supplements taken** | 1.15 | 0.93-1.43 |  |  |  |
| **Generic substitution**Φ |  |  |  |  |  |
| No | 1 |  |  | 1 |  |
| < 75% | **0.31** | **0.11-0.91** |  | **0.12** | **0.03-0.57** |
| ≥ 75% | 0.69 | 0.29-1.61 |  | **0.41** | **0.15-1.13** |
| **Patient information leaflet** **reading** |  |  |  |  |  |
| Never/sometimes | 1 |  |  |  |  |
| Always | **2.80**  | **1.29-6.10** |  |  |  |
| **GP visits in a year** |  |  |  |  |  |
| 0-2 | 1 |  |  |  |  |
| 3-5 | 1.08 | 0.45-2.61 |  |  |  |
| >5 | 1.15 | 0.46-2.91 |  |  |  |
| Cannot remember | 1.40 | 0.25-7.78 |  |  |  |
| OR= odds ratio; CI= confidence interval†: Univariate analysis adjusted only for clustering on patients chronic disorder. ‡: Adjustment was done for clustering on patients’ chronic disorder, health-related education, having family member with health-related education, age and number of vitamins/supplements (as continuous variables), and frequency of SPC reading. §: Age was used as a continuous variable.¶: If one was married or registered partnership and had total income: <43 057 or 43 057 -64 478€, was categorized as low income; 64 586-86 006 € you were categorized as medium income; >86 114€ you were categorized as high income. If you were divorced/ widow/widower/not married or other and had total income: < 43 057€ you were categorized as medium income; > 43 057€ you were categorized as high income. 1 Euro= 9.29 NOK, annual exchange rate for 2016.[10]Ϊ: High school education indicates secondary education with 9-12 years of education, and also education other than tertiary. Φ: The generic variable was then divided into three groups: no generic use (even though there was an available generic brand), using < 75% generic medicines, using ≥ 75% generic medicines. Patients with no choice of a generic substitution n=34 (14.2%). |

**Box 1.** Individual items of the Perceived Sensitivity to Medicines scale (PSM).

1. My body is very sensitive to medicines

2. My body overreacts to medicines

3. I usually have stronger reactions to medicines than most people

4. I have had a bad reaction to medicines in the past

5. Even very small amounts of medicines can upset my body.

© Professor Rob Horne University of London, 2013